Browse > Home / FDA News / Rx-360 Receives Mixed Reviews on Plan to Share Drug Industry Audits

Rx-360 Receives Mixed Reviews on Plan to Share Drug Industry Audits

August 25, 2009

Rx-360 Receives Mixed Reviews without interruption Plan to Share Drug Industry Audits
The drug industry is expressing some skepticism round relying on an Rx-360 Consortium plan to mode of action. and share supply-chain audits as the months-old consortium sets up moving groups toward that end. “It’s important that diligence understand what they’re acquisition and verify the information,” Steven Niedelman, senior consultant with Crowell & Moring, said at the FDAnews Supplier Quality Management Congress last week. Rx-360, what one. launched in June, would choose suppliers beneficial to audits based on portion input, and members can look on audit results on a subscription basis.

Written by Samanta · Filed Under FDA News